<DOC>
	<DOCNO>NCT01732510</DOCNO>
	<brief_summary>This 3-part study ass safety , tolerability , efficacy , pharmacokinetics ( PK ) , pharmacodynamics ( PD ) , immunogenicity MK-8226 participant moderate severe atopic dermatitis . Part 1 ( multiple rise dose study ) objectives find maximum tolerate dose ( MTD ) MK-8226 ass safety PK . Part 2 objective determine safety , PK , preliminary efficacy . Part 3 objective define safety PK , explore MK-8226 PK/PD model optimal dose range future study . The study terminate early due business reason 08 May 2014 ; final result analysis Part 1 ( efficacy , PK , safety , immunogenicity ) Part 2 ( safety , immunogenicity ) summarize .</brief_summary>
	<brief_title>A Study Intravenous MK-8226 Participants With Moderate-to-Severe Atopic Dermatitis ( MK-8226-003 )</brief_title>
	<detailed_description>Part 1 study multiple rise dose assessment safety , tolerability , pharmacokinetics MK-8226 period 12 week follow 20-week off-treatment follow-up period . Part 2 study assessment safety , tolerability , efficacy MK-8226 12 week follow 20-week off-treatment follow-up period . In Part 3 study , participant treat MK-8226 period 12 week follow 20-week off-treatment follow-up period evaluate pharmacokinetic pharmacokinetic correlation assist model dose range plan study .</detailed_description>
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<criteria>Body weight &gt; =40 kg Clinical diagnosis atopic dermatitis least 6 month prior Candidate systemic phototherapy ( i.e. , fail topical treatment ) Moderatetosevere disease define Body Surface Area ( BSA ) ≥10 % , EASI ≥12 , IGA ≥3 No clinically significant abnormality electrocardiogram No history active latent tuberculosis ( TB ) sign symptom suggestive TB No history active latent TB sign symptom suggestive TB History inadequate response stable ( ≥ 1 month ) regimen topical corticosteroid calcineurin inhibitor within 3 month screen visit Concurrent significant skin disease Any significant organ dysfunction within 6 month prior History clinically significant heart disease History neoplastic disease Positive hepatitis B , hepatitis C , human immunodeficiency virus ( HIV ) Infection require oral antibiotic within 2 week prior Receipt live virus vaccine within 4 week prior Inability refrain topical systemic therapy course study Had major surgery donate lose &gt; =1 unit blood within 4 week prior Participation another study within 4 week prior Current regular user illicit drug history drug alcohol abuse within 1 year prior Pregnant , breastfeeding , anticipate conceive course study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>